MPLT - MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - Click For Release
MPLT - MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - Click For Release
Story updates
11:01:32 AM UTC
SquawkNews
MPLT Maplight Therapeutics announces positive topline results from phase 2 zephyr trial of ml-007c-ma in schizophrenia Maplight Therapeutics - phase 2 zephyr trial of ml-007c-ma meets primary endpoint in schizophrenia - 210/3 mg bid dose shows significant panss improvement at week 5 in phase 2 trial - Ml-007c-ma well tolerated with no serious or drug-related severe adverse events - To proceed with additional registrational trial and engage FDA at end-of-phase 2
MPLT Maplight Therapeutics announces positive topline results from phase 2 zephyr trial of ml-007c-ma in schizophrenia Maplight Therapeutics - phase 2 zephyr trial of ml-007c-ma meets primary endpoint in schizophrenia - 210/3 mg bid dose shows significant panss improvement at week 5 in phase 2 trial - Ml-007c-ma well tolerated with no serious or drug-related severe adverse events - To proceed with additional registrational trial and engage FDA at end-of-phase 2